DOCSLIB.ORG

Custom Manufacturing in Thailand, Evonik in China

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Custom Manufacturing in Thailand, Evonik in China 10/2011 October Markets and Companies Markets and Companies Interview with Styrolution’s CEO THE NEWSPAPER FOR THE Expert Peter Pollak discusses the Roberto Gualdoni CHEMICAL AND fragmented world of fine chemicals Page 5 LIFE SCIENCE MARKE TS Pages 8 and 14 N EWSFLOW Market and Companies: Haltermann sold to H.I.G Europe, Dr. Uwe Nickel named new CEO. An Industry Full of Opportunity DuPont seeking buyers for two se- parate businesses: a polyester-film CPhI Highlights the Latest Trends in Pharma joint venture and one that makes powder-based paint. Bayer and Yunona Holdings have entered a memorandum of under- Markus Blocher Dr. Jörn Winterfeld standing to manufacture drugs in CEO, Dottikon Russia. Director Business Line Pharma/Agro at Wacker Biosolutions, Wacker AstraZeneca has announced it will be laying off about 400 employees in the U.S., primarily at its head- API Fine Chemicals quarters in Wilmington, Del. … Chemical exclusive synthesis partners Consolidation in the fine chemicals industry Lanxess has announced three in- need to possess a versatile technology will continue, since it is a very fragmented vestments totaling upwards of €30 “ portfolio like a Swiss army knife and be as industry. Many small players may vanish million in Brazil. ” “ ” precise and reliable as a Swiss watch. or merge to attain the so-called critical mass. Syngenta has posted a 21 % rise in This trend includes producers in China. its Q3 results over last year. More on Page 2 ▶ Jean Bléhaut Director of Marketing & Business Development, Novasep Dr. Martin Wienkenhöver Under Construction: CEO, CABB Both Solvay and Evonik are building hydrogen peroxide plants; Solvay Custom Manufacturing in Thailand, Evonik in China. Fine Chemicals Over the years, the new synthetic molecules …We see a strong growth in the The first production facilities in the developed in the pharmaceutical industry $1.4 billion expansion of BASF-YPC outsourcing of fine chemicals – especially Company have now begun opera- “ have become larger and more challenging ” of more challenging chemical syntheses. tions. “ ” to synthesize. More on Page 5 ▶ Wolfgang Schmitz Robert Hardy People: CEO, Aesica Dr. Thomas Büttner became CEO, Saltigo AllessaChemie’s president and CEO on Oct. 1, taking over from Almuth Poetz. Custom Manufacturing General Michael Träger, managing director …We see also growth potential in the In 10 years, our industry will be much and COO of Vestolit, has been ree- lected as chairman of Euro Chlor for pharmaceutical sector, because big pharma stronger, competitive and diverse with the another one-year term. “ companies are outsourcing more and more” “most significant contribution to the pharma- ” Kenneth Frazier will be succeeding to concentrate on their core strengths and ceutical market coming from emerging econo- Merck & Co. chairman Richard Clark emerging pharma companies continue to drive mies such as Brazil, Russia, China and India. on Dec. 1. new drug developments through innovation. Linde has appointed Thomas Bla- des as a new member of the exe- cutive board. Blades will succeed J. Kent Masters. Dr. Ralf Fink Dr. Andreas Dietrich Vice President and Head of Pharma Vice President Launch and Strategic Ingredients at BASF Events: Products, Boehringer Ingelheim There are several industry events coming up in November and De- General cember. Check out our event lis- APIs © askaja - Fotolia.com Cost pressure, strong growth in emerging tings for more details. While corresponding quality and regu- More on Page 19 ▶ countries, ongoing market consolidation latory understanding was still in need of “as well as the emergence of new regional or ” “ development, today’s Asian manufacturers” even global players and a significant higher have become better at responding to needs demand for performance excipients are which go beyond price. scenarios we want to be prepared for. ntgelt ntgelt bezahlt · 78719 E G· A The Powerhouse for API Solutions CPhI Worldwide Frankfurt, 25-27 October 2011 - Hall 4.2 – Stand 42F31 www.sintesicomunicazione.it · PF 11 05 64 · 64220 Darmstadt · Pressepost · DP G F.I.S. - Fabbrica Italiana Sintetici SpA Viale Milano, 26 - 36075 Montecchio Maggiore - (Vicenza) - Italy www.fisvi.com GIT GIT VERLA chemanager-online.com/en Page 2 MARKETS & COMPANIES CHEManager Europe 10/2011 CONTENT DECISIVE INFORMATION THE PORTAL AND NEWSPAPER FOR THE EUROPEAN CHEMICALS AND PHARMACEUTICAL MARKETS Front Page Packaging / Logistics 10 A Changing World for CMOs 16 Consolidation in Pharma a Win for Custom Manufacturing An Industry Full of Opportunity 1, 11–19 Fighting Counterfeits 10 M. Griffiths, Carbogen Amcis; W. Schmitz, Saltigo; M. Cassidy, CPhI Highlights the Latest Trends in Pharma Enhanced Safety For Pharmaceutical Packaging SAFC; J. Bléhaut, Novasep Oliver Naucke, Uhlmann Pac-Systeme Fine Chemicals Developing Well in 2011 16, 17 Markets & Companies 2–9 Agro Segment Showing Particularly Strong Growth Let There Be Light! Dr. Martin Wienkenhöver, CABB; Dr. Peter Seufer-Wasserthal, Codexis; Specialty Chemicals in China 4 How Industrial Packaging Can Boost Sustainability Measures Dr. Jörn Winterfeld, Wacker What's So Special About It? Dr. Clemens Willée, CEO, Mauser Group Dr. Kai Pflug, CEO, Management Consulting and Dr. Bernhard Hartmann, Managing Director, A.T. Kearney China Functional Ingredients 17 Excipients Not Just Additives Anymore CPhI 2011 11–19 Dedicated To Styrenics 5 Hans Ole Klingenberg, Novozymes Styrolution Starts Operations, Positioned for Ei Gude, Wie? 11 Profitable Growth and Long-term Success ´As Reliable as a Swiss Watch´ 18 Roberto Gualdoni, Styrolution The CPhI Returns to Frankfurt Innovation Expected from API Manufacturers Interview with UBM Live brand directors Annemieke Timmers (CPhI) © Nmedia/fotolia.com Markus Blocher, Dottikon; Dr. Andreas Dietrich, Boehringer Ingelheim; A Passion For Chemistry 6 and Haf Cennydd (ICSE, P-MEC & BioPh) Heinz Sieger, CU Chemie Uetikon Ferak Berlin: A Famili Company with a Global Reach Interview with Thomas Gründemann, CEO, Ferak Berlin Game Change 12, 13 Center Stage: Emerging Countries 19 online.com/en chemanager - chemanager Pharma's Future with a Disaggregated Supply Chain APIs in China 7 All-round Pharma Service Providers See Potential in Asia, Elsewhere chemanager - Pharma Industry Booming in Asia Michael Jarosch, Ulrich Korneck, Camelot Management Consultants Robert Hardy, Aesica; Dr. Ralf Fink, BASF; Burghard Freiberg, Iris Zhao, Frost & Sullivan Merck Millipore online.com /en Breaking Taboos 13 A Fragmented Industry 8, 14 Pharma Must Make Big Changes to Survive Peter Pollak on the World of Fine Chemicals Interview with Ulrich Korneck and Michael Jarosch, People · Events · Awards 19 www.gitverlag.com Interview with Dr. Peter Pollak, Fine Chemical Business Consultant Camelot Management Consultants Flexibility, Internationality and Know How 9 API Sourcing in China and India 15 At A Glance 20 Industry Service: Expectations on Is Asia the Only Option for the Future Technical Service Providers Growing Index 20 Interview with Dr. Joachim Kreysing, Bob Kennedy, Manager of Industry Research, Thomson Reuters and executive vice president of the BIS Group Molly Bowman, Manager Small Molecule Research, Thomson Reuters Imprint 20 AkzoNobel Completes Haltermann Sold to H.I.G Europe Bayer Joins Yunona Holdings Schramm Holding Acquisition Haltermann, a subsidiary of Dow, For Drug Manufacturing has been acquired by H.I.G. Europe, AkzoNobel has completed its ac- in 2010 of €115 million and employ the European arm of H.I.G. Capital. Bayer and Yunona Holdings, rep- quisition of more than 95 % of the around 800 people. In addition to The CEO of the new Haltermann resenting the Ural Pharmaceutical shares of coatings manufacturer the Schramm deal, the company is Dr. Uwe Nickel, formerly board Cluster (UPC) of Russia have entered Schramm Holding. Based in Ger- expects to finalize the acquisition of member of Clariant and head of the Dr. Uwe Nickel a memorandum of understanding CEO, Haltermann many and listed on the Hong Kong Korean SSCP’s coatings business as chemical practice of the consulting to manufacture drugs in Russia. Stock Exchange, Schramm manufac- of Nov. 1. SSCP was also the majority firm Arthur D. Little. At produc- The companies said they intend to tures and markets coatings for plas- shareholder of Schramm until the tion sites in Hamburg and Speyer, defined specifications. Haltermann establish themselves in the fields of tics, metals and electrical insulation Akzo deal. Germany, Haltermann produces is also a supplier of high-purity n-, production, marketing and distribu- as well as coil coatings for alumi- complex test and specialty fuels as iso- and cyclopentanes employed tion of pharmaceutical products in num. They achieved global revenues J well as various solvents based on as blowing agents in the production Russia, the website inpharm.com hydrocarbons with short to medi- of polystyrene and polyurethane reported. The cluster has received economic development program be- um chain length, all with narrowly foams. J funds worth 27.3 billion rubles tween 2010 and 2015. Lanxess to Invest €30 Million in Brazil (around $860 million) from Russia’s J Lanxess has announced three invest- will go on stream in mid-2013. The ments totaling €30 million in Brazil. other plant will produce the rubber ECHA Board Decisions in Fee Disputes Ashland Opens Mumbai The company said investments will additives Rhenogran as well as Rhe- support the growing trend toward noshape curing bladders. The European Chemicals Agency’s registration fee, the particular cir- Technical Center green mobility in the Latin American In the third investment, Lanxess (ECHA) board of appeal has pub- cumstances of the cases are differ- country. The investments include is re-engineering parts of its plant in lished its first two final decisions on ent. The board of appeal decided in Ashland has opened a new techni- the construction of two new plants Triunfo, Rio Grande do Sul, in order appeals against decisions adopted favor of the appellant in one case cal center in Mumbai, India. The at the company’s Porto Feliz site in to produce EPDM rubber from bio- by ECHA under the Reach Regula- and in favor of ECHA in the other.
Load more

Recommended publications
  • Technical Information
    Technical Information Antibiotic Assay Medium No.1 (Seed Agar) Product Code : DM1003 Application: - Antibiotic Assay Medium No.1 (Seed Agar) is used in the microbiological assay of beta-lactam and other antibiotics. Composition** Ingredients Gms / Litre Peptic digest of animal tissue (Peptone) 6.000 or detecting faecal coliforms drinking in water waste water, seawater and foods samples by MPN Method. Casein enzymic hydrolysate 4.000 Yeast extract 3.000 Beef extract 1.500 Dextrose 1.000 Agar 15.000 Final pH (at 25°C) 6.6±0.2 **Formula adjusted, standardized to suit performance parameters Principle & Interpretation The potency of an antibiotic can be determined by chemical, physical and biological methods. An assay is performed to determine the ability of an antibiotic to kill or inhibit the growth of living microorganisms. Biological tests offer the most convenient m eans of performing an assay (1), since a reduction in the antimicrobial activity of a specific antibiotic reveals changes that is not usually displayed by chemical methods (2). Antibacterial susceptibility testing may be performed by either dilution (turbidimetric) or diffusion methods. The choice o f methodology is based on many factors, including ease of performance, flexibility and use of automated or semi-automated devices for both identification and susceptibility testing (3). Grove and Randall have elucidated antibiotic assays and media in their comprehensive treatise on antibiotic assays (4). Antibiotic Assay Medium No.1 is used in the microbiological assay of ß-lactam and other antibiotics. These media are prepared according to the specifications detailed in various pharmacopoeias (2-6) and by the FDA (7).
    [Show full text]
  • Contractor Orientation Manual
    Contractor Orientation Manual KALAMAZOO CONTRACTOR ADMINISTRATION TABLE OF CONTENTS INTRODUCTION......................................................................................................................................4 DEFINITIONS...........................................................................................................................................4 1. Supplier: ........................................................................................................................................4 2. Contractor: ………………………………………………………………………………………4 3. Pfizer Contact: ...…………………………………………………………………………….4 4. Kalamazoo Contractor Administration: ……………………………………………………..4 GENERAL INFORMATION....................................................................................................................5 1. Company Access ...........................................................................................................................5 2. Vehicle Admittance & Parking .....................................................................................................5 3. Tobacco Products ..........................................................................................................................6 4. Cafeterias and Snack Bars..............................................................................................................6 5. The Federal Food, Drug and Cosmetic Act................................................................................... 6 6. Good Manufacturing Practices
    [Show full text]
  • Evolution of a Regulatory Framework for Pharmaceuticals Derived from Genetically Modified Plants
    Review Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants Armin Spo¨k1*, Richard M. Twyman2, Rainer Fischer3, Julian K.C. Ma4 and Penelope A.C. Sparrow5* 1 Inter-University Research Centre for Technology, Work and Culture (IFZ), Schlo¨ gelgasse 2, A-8010 Graz, Austria 2 Department of Biology, University of York, Heslington, York, YO10 5DD, UK 3 Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Aachen, Germany 4 St George’s Hospital Medical School, Cranmer Terrace, London, SW17 0RE, UK 5 John Innes Centre, Norwich Research Park, Norwich, NR4 7UH, UK The use of genetically modified (GM) plants to synthes- phase II clinical trials, respectively [6]. In 2006, the United ize proteins that are subsequently processed, regulated States Department of Agriculture (USDA) licensed a poul- and sold as pharmaceuticals challenges two very differ- try vaccine produced in cultured tobacco cells [7]. Since ent established regulatory frameworks, one concerning then, several products derived from crop plants have also GM plants and the other covering the development of reached late development stages, including human insulin biotechnology-derived drugs. Within these regulatory and carp growth hormone produced in safflower. These are systems, specific regulations and guidelines for plant- expected to reach the market between 2008 and 2010 (see made pharmaceuticals (PMPs) – also referred to as plant- Table 1). derived pharmaceuticals (PDPs) – are still evolving. The PMPs present two major challenges for the regulatory products nearing commercial viability will ultimately bodies. Regulators of agricultural biotechnology are con- help to road test and fine-tune these regulations, and fronted with a novel type of crop use, and drug regulators might help to reduce regulatory uncertainties.
    [Show full text]
  • New Deals, New Investments in Chemical Manufacture
    Chemical Manufacture New deals, new investments in chemical manufacture We review some of the most recent contracts, investments and merger and acquisition activities in the highly competitive field of fine chemical manufacture. he manufacture of pharmaceutical fine chemical business is a major player in the global fine chemical sector, intermediates and ingredients remains probably the with a leading position in the supply of contract manufacturing Tmost competitive sector of the chemical industry and services to the agrochemicals, pharmaceutical and speciality there continue to be major changes in the structure of the chemical industries. The acquisition included all Avecia Fine sector and in the geographical spread of major manufacturing Chemicals’ assets and operations on the 65 hectare site at faciltiies, with investments in China and India playing a leading Grangemouth, UK. All 310 Avecia Fine Chemicals’ employees part in companies’ moves to acquire stronger positions. This were included in the transaction. In 2004, the business article looks at just a few of the recent developments. recorded sales of £38 million. Avecia Fine Chemicals Limited now operates as KemFine UK Acquisition of ozone chemistry technology Ltd. Tom Shields is the managing director, and is based at the In February, Dishman Pharmaceuticals & Chemicals Ltd Grangemouth site. KemFine, previously Kemira Fine Chemicals acquired IO3S Ltd of Bern, Switzerland, through its 100% Oy, was created via an MBO of the business from Kemira in wholly owned Switzerland based subsidiary company M/s. 2004. 3i, a world leader in the private equity and venture Dishman Switzerland Ltd. The Assets base of IO3S is currently capital sector, supported the management team in the about $2 million but Dishman says the acquisition was transaction and in the equity funding.
    [Show full text]
  • Chemacx Vendor List
    ChemACX Vendor List -A B C D E F G H I J K L M N O P Q R S T U V W X Y Z- -#- APAC PHARMACEUTICAL ACTIVATE SCIENTIFIC GMBH AQCHEM LLC ADESIS INC. 1K SCIENTIFIC ASW MEDCHEM, INC. ADVAMACS 3A PHARMATECH AURUM PHARMATECH LLC ADVANCE RESEARCH CHEMICALS, INC. 3B SCIENTIFIC CORP. AARON CHEMISTRY ADVANCED AROMATICS, L.P. 3RCHEM ABAMACHEM LTD ADVANCED ASYMMETRICS, INC. 8S LABORATORIES LLC ABBEY COLOR ADVANCED CHEMBLOCKS INC. Updated Aug. 2018 -A- ABBOTT LABORATORIES CHEMICAL DIVISION ADVANCED CHEMTECH A&A LIFE SCIENCE INC. DBA ABBY PHARMATECH LLC ADVANCED MOLECULAR AVACHEM SCIENTIFICS TECHNOLOGIES PTY LTD ABERJONA LABORATORIES A&C PHARMTECH, INC ADVANCED SCIENTIFIC ABOVCHEM LLC INTERNATIONAL, LLC A&J PHARMATECH ABSOLUTE CHIRAL ADVANCED SYNTHESIS A.G. SCIENTIFIC Updated July 2018 TECHNOLOGIES, S.A. Updated Jan. 2018 ACADECHEM COMPANY LIMITED ADVANCED TECHNOLOGY & A1 BIOCHEM LABS INDUSTRIAL CO., LTD. Updated Sep. 2018 ACADEMIQUE PHYTOCANADA AIMS FINE CHEMICALS INC. AA BLOCKS LLC ACCELA CHEMBIO CO., LTD. New Sep. 2018 Updated June 2018 AIR PRODUCTS & CHEMICALS, INC. AB CHEM TECHNOLOGIES LLC ACCELEDEV CHEMICAL LLC AJINOMOTO - AMINO ACID DEPARTMENT ABCR GMBH & CO. KG ACCUSTANDARD, INC. ALBANY MOLECULAR RESEARCH, INC. ABSCO LTD ACE SYNTHESIS LLC ALBEMARLE CORPORATION ABX ADVANCED BIOCHEMICAL ACENTEX SCIENTIFIC, INC. COMPOUNDS ALBRIGHT & WILSON AMERICAS ACESYS PHARMATECH AECHEM ALCHEM INTERNATIONAL LIMITED ACETO CORPORATION AK SCIENTIFIC, INC. ALCHEM PHARMTECH, INC. Updated Sep. 2018 ACHEMICA ALDLAB CHEMICALS, LLC AKL RESEARCH LLP ACINOPEPTIDE CO. LTD ALDRICH AOBCHEM USA ACME BIOSCIENCE, INC. ALFA AESAR AOKBIO CO., LTD ACROS ORGANICS Updated Apr. 2018 ALFA CHEMISTRY ACROS ORGANICS – USA New June 2018 AOKCHEM CO., LTD.
    [Show full text]
  • A Fine Art How Much of the Fin E Chemicals Market Can Pharma Lay Claim to Today- and in the Future? Jan Ramakers, Jan Ramakers Fine Chemical Consulting Group Writes
    E CHEMICALS • A fine art How much of the fin e chemicals market can pharma lay claim to today- and in the future? Jan Ramakers, Jan Ramakers Fine Chemical Consulting Group writes ine chemicals, speciality chemicals, and performance chemicals are some of the various names used to describe products in the Fine chemical market in 2014 Fhigh-value end of the chemical market. In order to avoid any - total value $127.7bn - confusion, it is good to keep in mind that fine chemicals ore defined as (high value) chemical products that ore sold for what they ore, ie for Other Pharma their precise chemical structure. Speciality chemicals, often also referred Food a to as performance chemicals, are (high value) chemical products that 4% ore sold for what they do. So an intermediate used in the manufacture Pigments& of a specific API is a fine chemical as it needs to have a very specific 3% chemical structure; a different chemical structure cannot be used. Fine chemicals are used across a wide range of market segments, and it is easy enough to make a list that features 40-50 different application intermediates areas. 10% The products end up in speciality chemicals markets, for instance as Fragrances active ingredients in biocide formulations, as additives for plastics and 7% coatings, or as active ingredients in cosmetics and toiletries. Some are Figure 1. used as intermediates in the manufacture of liquid crystal displays, and so on. Many of those end markets are quite large, but most of them are fairly small as an outlet for fine chemicals.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2007/0122887 A1 Klopprogge Et Al
    US 2007.0122887A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0122887 A1 Klopprogge et al. (43) Pub. Date: May 31, 2007 (54) GENE VARIANTS CODING FOR PROTEINS (30) Foreign Application Priority Data FROM THE METABOLIC PATHWAY OF FNE CHEMICALS Dec. 18, 2003 (DE)..................................... 103 59 661.5 (75) Inventors: Corinna Klopprogge, Mannheim (DE); Publication Classification Oskar Zelder, Speyer (DE); Burkhard Kroger, Limburgerhof (DE); Hartwig (51) Int. Cl. Schroder, Nublock (DE); Stefan CI2P I3/04 (2006.01) Haefner, Ludwigshafen (DE); Uwe CI2P I3/08 (2006.01) Ruffer, Meckenheim (DE); Claudia C7H 2L/04 (2006.01) Isabella Graef, Lampertheim (DE) CI2N 9/10 (2006.01) CI2N 15/74 (2006.01) Correspondence Address: CI2N I/2 (2006.01) LAHIVE & COCKFIELD, LLP ONE POST OFFICE SQUARE (52) U.S. Cl. ......................... 435/106; 435/115; 435/193; BOSTON, MA 02109-2127 (US) 435/252.3; 435/471; 536/23.2 (73) Assignee: BASF Aktiengesellschaft, Ludwigshafen (DE) (57) ABSTRACT (21) Appl. No.: 10/583,404 (22) PCT Filed: Dec. 16, 2004 The present invention relates to mutated nucleic acids and proteins of the metabolic pathway of fine chemicals, to (86). PCT No.: PCT/EPO4/14338 processes for preparing genetically modified producer organisms, to processes for preparing fine chemicals by S 371(c)(1), culturing said genetically modified organisms and to said (2), (4) Date: Jun. 16, 2006 genetically modified organisms themselves. US 2007/O 122887 A1 May 31, 2007 GENEVARLANTS CODNG FOR PROTEINS FROM and optimized C yield, there is a constant need for further THE METABOLIC PATHWAY OF FINE improving the productivity of said organisms.
    [Show full text]
  • Fine Chemical Intermediates
    Fine Chemical Intermediates On Request (OR) / Main Structure Identification Characteristics Regular Applications Production (RP) Phosgene derivatives Methyl chloroformate Assay: min. 99% by area Organic reagent for RP O MCF, Methyl chlorocarbo- introduction of the nate, Chloroformic acid Appearance: colourless to methoxycarbonyl methyl ester pale yellow liquid group, synthesis of Packaging: 160 kg drum, carbonates, Cl O CAS Reg. No. 79-22-1 ISO tank carbamates, anhydrides etc. Ethyl chloroformate Assay: min. 98.5% by area Organic reagent for RP O ECF, Ethyl introduction of the chlorocarbonate, Appearance: colourless to ethoxycarbonyl group, Chloroformic acid ethyl pale yellow liquid synthesis of ester Packaging: 160 kg drum, carbonates, Cl O ISO tank carbamates, CAS Reg. No. 541-41-3 anhydrides etc. n-Propyl chloroformate Assay: min. 98% by area Organic reagent for OR O nPCF, n-Propyl chlorocar- introduction of the n- bonate, Chloroformic acid Appearance: colourless to propoxycarbonyl propyl ester pale yellow liquid group, synthesis of Cl O Packaging: ISO tank carbonates, CAS Reg. No. 109-61-5 carbamates, anhydrides etc. Isopropyl chloroformate Assay: min. 98.5% by area Organic reagent for OR O iPCF, 2- introduction of the Propylchloroformate, Appearance: clear colour- isopropoxycarbonyl Chloroformic acid less to pale yellow liquid group, synthesis of isopropyl ester Packaging: ISO tank carbonates, Cl O carbamates, CAS Reg. No. 108-23-6 anhydrides etc. n-Pentylchloroformate Assay: min. 98.5% by area Organic reagent for OR n-Pentylchlorocarbonate, introduction of the n- O Chloroformic acid pentyl Appearance: colourless pentoxycarbonyl ester liquid group, synthesis of Packaging: 190 kg drum carbonates, Cl O CAS Reg. No. 638-41-5 carbamates, anhydrides etc.
    [Show full text]
  • Cbn Smis Intervention of March 2, 2017 - Sales
    CBN SMIS INTERVENTION OF MARCH 2, 2017 - SALES S/N CUSTOMERS NAME AMOUNT (US$) RATE (N/US$) ITEM OF IMPORT FORM 'M' NUMBER LC NUMBER DATE OPENED MATURITY DATE BANK 45- DAY TENOR 1 SMSAM SYSTEM LTD 20,500.00 380.00 SOFTWARE MF20160100500 22157280377 UNITY 2 PROCTER AND GAMBLE NIGERIA LIMITED 52,623.11 375.00 KRAFT BLEACHED WOODPULP 25.0CM MF20160086965X 152.0CM 516 (RAW MATERIAL5067600865 FOR PRODUCING7/28/16 PAMPERS) 1/17/17 CITI 3 PROCTER AND GAMBLE NIGERIA LIMITED 92,391.70 375.00 KRAFT BLEACHED WOODPULP CMC530MF20160086945 (RAW MATERIAL FOR PRODUCING5063600865 PAMPERS)7/28/16 10/28/16 CITI 4 PROCTER AND GAMBLE NIGERIA LIMITED 89,851.22 375.00 BG PA BFLY S2 10 SMP SSA; BG PA SF BFLYMF20160095066 S2 80 JP SSA; BG PA SF 5064600890BFLY S4 64 JP8/16/16 SSA; BG PA SF BFLY S3 911/4/16 SMP SSA; BG PA SF BFLY S3CITI 72 JP SSA (RAW MATERIAL FOR PRODUCING PAMPERS) 5 PROCTER AND GAMBLE NIGERIA LIMITED 214,060.00 375.00 AQUALIC CA L521 (RAW MATERIAL FORMF20160091918 PRODUCING PAMPERS) 5069600877 8/8/16 11/28/16 CITI 6 PROCTER AND GAMBLE NIGERIA LIMITED 183,480.00 375.00 AQUALIC CA L521 (RAW MATERIAL FORMF20160094963 PRODUCING PAMPERS) 5063600890 8/16/16 11/28/16 CITI 7 PROCTER AND GAMBLE NIGERIA LIMITED 53,243.14 375.00 KRAFT BLEACHED WOODPULP 50.8CM MF20160095724X 120.0CM 516 (RAW MATERIAL5062600891 FOR PRODUCING8/17/16 PAMPERS) 10/28/16 CITI 8 PROCTER AND GAMBLE NIGERIA LIMITED 61,537.41 375.00 POLYESTER NONWOVEN ACQUISITIONMF20160093058 LAYER (43G/M2) AQL 2+ WHITE5061600876 80 MM (RAW8/8/16 MATERIALS FOR PRODUCING1/2/17 PAMPERS) CITI 9 PROCTER AND GAMBLE NIGERIA LIMITED 42,302.05 375.00 980 - U- TAPES 13MM WIDTH 13MM ADHMF20160086914 U GLUE 8 BOX/FUM.
    [Show full text]
  • Development of Simple and Efficient Synthetic Strategies For
    Tiina Saloranta Development of Simple and Efficient Synthetic Strategies for Production of Fine Chemicals of Pharmaceutical Relevance of Pharmaceutical Production of Fine Chemicals for Strategies Synthetic of Simple and Efficient Development Development of Simple and Efficient Synthetic Strategies for Production of Fine Chemicals of Pharmaceutical Relevance ‒ Metal‐Mediated Allylation Combined with Applied Catalysis Tiina Saloranta ISBN 978‐952‐12‐2743‐1 Laboratory of Organic Chemistry Painosalama Oy – Turku, Finland 2012 Department of Chemical Engineering Division of Natural Sciences and Technology Åbo Akademi University Åbo, Finland 2012 2012 Development of Simple and Efficient Synthetic Strategies for Production of Fine Chemicals of Pharmaceutical Relevance ‒ Metal‐Mediated Allylation Combined with Applied Catalysis Tiina Saloranta Laboratory of Organic Chemistry Department of Chemical Engineering Division of Natural Sciences and Technology Åbo Akademi University Åbo, Finland 2012 SUPERVISOR AND CUSTOS Professor Reko Leino Laboratory of Organic Chemistry Åbo Akademi University Åbo, Finland OPPONENT Professor Shū Kobayashi Department of Chemistry The University of Tokyo Tokyo, Japan REVIEWERS Professor Pavel Kočovský Department of Chemistry University of Glasgow Glasgow, United Kingdom and Professor Guy Lloyd‐Jones School of Chemistry University of Bristol Bristol, United Kingdom ISBN 978‐952‐12‐2743‐1 Painosalama Oy – Turku, Finland 2012 Helky laulu Auran rantain silmä kirkas salamoi, kaiu maine kauas kantain minkä kunto kansan voi! Täällä Suomen synnyinmuistot, täällä työn ja tiedon puistot virttä vapauden soi virttä vapauden soi. :,: Helky laulu, kaiu maine, virttä vapauden soi.:,: Auran rantamilla tähti syttyi päälle Suomenmaan, Auran rantamilta lähti onni maahan ihanaan: Kristinuskon, tiedon valta nosti heimot kaikkialta turvaks armaan synnyinmaan turvaks armaan synnyinmaan. :,: Helky laulu, kaiu maine, virttä vapauden soi.:,: Puhkes uudet tertut tuomeen, aika aatteet uudet toi, Auran rantamilta Suomeen koitti kirkas huomenkoi.
    [Show full text]
  • Development of Bio-Based Fine Chemical Production Through Synthetic Bioengineering Hara Et Al
    Redesign Design Computer Simulation Common Source Metabolic Data Artificial Metabolic Map Metabolic Engineering Substrate Gene Manipulation Co- Enzyme enzyme Heterologous Fine chemical expression Overexpression Enzymatic Microbial Down regulation Fine chemical Fine chemical Deletion Synthesis Fermentation Mutation Development of bio-based fine chemical production through synthetic bioengineering Hara et al. Hara et al. Microbial Cell Factories 2014, 13:173 http://www.microbialcellfactories.com/content/13/1/173 Hara et al. Microbial Cell Factories (2014) 13:173 DOI 10.1186/s12934-014-0173-5 REVIEW Open Access Development of bio-based fine chemical production through synthetic bioengineering Kiyotaka Y Hara1, Michihiro Araki1, Naoko Okai1, Satoshi Wakai1, Tomohisa Hasunuma1 and Akihiko Kondo2* Abstract Fine chemicals that are physiologically active, such as pharmaceuticals, cosmetics, nutritional supplements, flavoring agents as well as additives for foods, feed, and fertilizer are produced by enzymatically or through microbial fermentation. The identification of enzymes that catalyze the target reaction makes possible the enzymatic synthesis of the desired fine chemical. The genes encoding these enzymes are then introduced into suitable microbial hosts that are cultured with inexpensive, naturally abundant carbon sources, and other nutrients. Metabolic engineering create efficient microbial cell factories for producing chemicals at higher yields. Molecular genetic techniques are then used to optimize metabolic pathways of genetically and metabolically well-characterized hosts. Synthetic bioengineering represents a novel approach to employ a combination of computer simulation and metabolic analysis to design artificial metabolic pathways suitable for mass production of target chemicals in host strains. In the present review, we summarize recent studies on bio-based fine chemical production and assess the potential of synthetic bioengineering for further improving their productivity.
    [Show full text]
  • Chemical Industry of the Future: New Biocatalysts
    NEW BIOCATALYSTS: ESSENTIAL TOOLS FOR A SUSTAINABLE 21st CENTURY CHEMICAL INDUSTRY Sponsored by Altus Genencor International, Inc. Cargill, Inc. Chevron Council for Chemical Research DSM E.I. DuPont de Nemours & Co. Maxygen U.S. Department of Commerce, NIST/ATP U.S. Department of Defense, Office of Naval Research U.S. Department of Energy, Energy Efficiency and Renewable Energy, Office of Industrial Technologies Utah State University Biotechnology Center Facilitation by Energetics, Inc. Sponsors Council for Chemical Research ® Table of Contents 1 Section I. Executive Summary 3 Section II. Introduction 7 Section III. The Visioning Process and Drivers 9 Section IV. The Present State of Biocatalysts 13 Section V. The Workshop 19 Section VI. Implementation 27 Section VII. Success Factors in Implementing the R & D in the Roadmap 33 Appendix A 34 Appendix B 36 List of Participants 37 Contact Information 38 Acknowledgments 2 We wish to thank the sponsors listed on the front cover for their support, without which this workshop could not have taken place nor could this report have been written. Special thanks to Genencor for use of their facilities and to Jack Huttner, Richard LaDuca, Jim Sjoerdsma, and Nancy Shaw for their hospitality. The authors thank the planning group and participants in the workshop for their many suggestions and careful review of the several drafts. Special credit is due Brian Davison and David Boron for their contribu- tions and graphics. Technical assistance by Mary Donahue, graphic designer, and Georgia Herod, editor, was superb. Pamela Garcia served as the workshop secre- tariat and did an excellent job in a complex organizational task.
    [Show full text]